孕妇对参与寨卡病毒疫苗试验的态度
一项针对128名孕妇及产后妇女的调查显示,77%的受访者愿意参与至少一项寨卡病毒疫苗试验,且对灭活疫苗试验的接受度显著高于减毒活疫苗试验(p<0.0001)和核酸疫苗试验(p<0.0444)。参与动机包括孕妇和非孕妇研究证据、保护胎儿、疫苗安全性和医生推荐。
要点
- 77%的孕妇及产后妇女愿意参与至少一项寨卡病毒疫苗试验。
- 灭活疫苗试验接受度显著高于减毒活疫苗(p<0.0001)和核酸疫苗(p<0.0444)。
- 参与动机包括研究证据、保护胎儿、疫苗安全性和医生推荐。
核心结论
- 多数孕妇愿意参与寨卡病毒疫苗试验,但不同疫苗平台的接受度存在差异。
研究设计与样本
- 在马萨诸塞州总医院产前保健机构招募128名孕妇和近期产后妇女完成问卷调查。
主要发现
- 77%的妇女接受参与至少一项假设的寨卡病毒疫苗试验。
- 灭活疫苗试验接受度显著高于减毒活疫苗试验(p<0.0001)和核酸疫苗试验(p<0.0444)。
- 参与动机包括孕妇和非孕妇研究证据、保护婴儿免受寨卡感染、疫苗安全性认知和医生推荐。
临床怎么用
- 研究结果可为寨卡病毒疫苗研究议程、候选疫苗优先排序和试验设计提供参考。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: As Zika virus infection during pregnancy can cause a range of congenital anomalies, pregnant women may be a target population for vaccination in future outbreaks. Their inclusion in vaccine trials is critical to ensure safe and effective vaccines in pregnancy. Though many vaccine candidates are in development, pregnant women's willingness to participate in Zika virus vaccine research is unknown. This study aims to describe pregnant women's attitudes toward Zika virus vaccine research participation, as well as perceived barriers to and facilitators of enrollment. METHODS: Pregnant and recently postpartum women (n = 128) attending prenatal care at Massachusetts General Hospital completed surveys querying their willingness to participate in four hypothetical Zika virus vaccine trials and their motivations for participation. Demographics, information on prior Zika virus exposure, and vaccine acceptance were collected. RESULTS: Most women (77%) accepted participation in at least one hypothetical Zika virus vaccine trial, and women were significantly more likely to accept prospective enrollment in an inactivated vaccine trial compared to a live-attenuated vaccine trial (p-value <0.0001) or a nucleic acid-based vaccine trial (p-value <0.0444). Important motivators for participation included evidence from research with pregnant and non-pregnant people, a desire to protect the baby from Zika, perceptions of vaccine safety, and provider recommendation. CONCLUSIONS: A majority of women in this cohort were willing to participate in a Zika virus vaccine trial while pregnant, however, differences in acceptance exist between vaccine platforms. The high value placed on evidence by participants highlights the importance of gathering and communicating pregnancy-specific data to potential research participants and their providers. Women's motivations for accepting research participation during pregnancy are important to inform the Zika virus vaccine research agenda, candidate prioritization, and trial design.
引用
- Goldfarb IT, Jaffe E, James K, et al. Pregnant women's attitudes toward Zika virus vaccine trial participation. Vaccine. 2018. PMID: 30268731. doi:10.1016/j.vaccine.2018.09.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。